St. Louis Breast Cancer Tissue Registry

描述(由申请人提供) 圣路易斯乳腺癌组织登记处是过去9年来合作成立国家癌症研究所合作乳腺癌组织资源的四个机构之一。该小组的任务是组织、评估、维护和分发乳腺癌存档标本，以及有关临床治疗、结果和肿瘤病理的详细数据，以促进对新的诊断和预后肿瘤标记物的研究。从癌症登记记录、临床图表、病理报告和5年患者对复发和生命状态的随访中收集的大量病例数据大大增强了肿瘤标志物表达数据的重要性。CBCTR拥有来自美国4个不同地区、不同地理和种族的9000多个样本，为评估单一医疗机构或生物技术公司的研究人员无法轻易获得的乳腺癌标志物提供了一个独特的、具有社区医疗中心患者群体代表性的样本收集。CBCTR机构的PL的综合专业知识包括临床肿瘤学、乳腺组织病理学、临床实验室操作、临床试验以及共享资源和癌症研究实验室。对临床数据和肿瘤分类的持续审计、新组织筛选技术(组织微阵列)的开发、对资源标本使用申请的重大科学和统计审查，以及适中的服务费，进一步增加了该资源在支持许多研究研究方面的特殊价值。在接下来的三年里，我们将继续履行合作协议的职责，包括1)与CBCTR的所有成员以协调的结构工作，向研究人员提供现有的组织和数据；2)与CBCTR的所有成员合作，根据NCI和研究评估小组(REP)的建议，为组织微阵列的设计和构建提供样本；3)继续与IMS中央数据库一起监测、更新和交流与我们的病例相关的数据收集；4)与所有站点、NCI、IMS和代表成员合作，以实现NCI的目标并向癌症研究社区宣传这一资源以及5)计划获取和收集更多的乳腺癌组织，无论是存档的还是新鲜的/冷冻的，以补充我们有限的收集。

DESCRIPTION (provided by applicant) The St. Louis Breast Cancer Tissue Registry is one of four institutions that have collaborated for the past 9 years to form the Cooperative Breast Cancer Tissue Resource of the National Cancer Institute. The mission of this group has been the organization, evaluation, maintenance, and distribution of archival breast cancer specimens coupled with detailed data on clinical treatment, outcome, and tumor pathology to facilitate research investigations of new diagnostic and prognostic tumor markers. The significance of tumor marker expression data is greatly enhanced by the extensive case data compiled from cancer registry records, clinical charts, pathology reports, and >5 years patient follow-up for recurrence and vital status. With more than 9000 specimens from 4, geographically and ethnically, diverse regions of the US, the CBCTR provides a unique collection, representative of community medical center patient populations, for evaluation of breast cancer markers that is not readily available to investigators at single medical institutions or biotechnology companies. The combined expertise of the Pl's at the CBCTR institutions include clinical oncology, breast tissue pathology, clinical laboratory operations, clinical trials, and shared resource & cancer research laboratories. Continuing audits of clinical data and tumor classification, development of new tissue screening technologies (tissue microarrays), significant scientific and statistical review of applications for use of the Resource specimens, and moderate service fees further add to the exceptional value of this Resource in the support of many research studies. Over the next 3 year period we will continue to fulfill the responsibilities of a cooperative agreement including 1) work with all members of the CBCTR in a coordinated structure to provide existing tissue and data to researchers, 2) work with all CBCTR members to provide specimens for design and construction of Tissue Microarrays as recommended by the NCI and Research Evaluation Panel (REP), 3) continue to monitor, update, and communicate, with the IMS Central Database, the collection of data linked to our cases, 4) cooperate with all sites, NCI, IMS, and REP members to achieve NCI goals and to publicize this Resource to the cancer research community, and 5) to plan the acquisition and data collection for additional breast cancer tissues, either archival or fresh/frozen, to replenish our finite collection.